Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
292.03
+7.19 (2.52%)
At close: May 12, 2026, 4:00 PM EDT
291.95
-0.08 (-0.03%)
After-hours: May 12, 2026, 7:31 PM EDT
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
| Dr. Pushkal P. Garg M.D. | Executive VP & Chief Research & Development Officer |
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director |
| Mr. Bryan Andrew Supran J.D. | Chief Legal Officer |
| Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
| Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer |
| Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer |
| Ms. Christine Regan Akinc | Chief Corporate Communications Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 8-K | alny-20260430.htm |
| 2026-04-30 | 10-Q | alny-20260331.htm |
| 2026-04-06 | DEF 14A | alny-20260406.htm |
| 2026-03-04 | 8-K | alny-20260302.htm |
| 2026-02-12 | S-8 | alny2026forms-8.htm |
| 2026-02-12 | 10-K | alny-20251231.htm |
| 2026-01-12 | 8-K | alny-20260111.htm |
| 2025-12-11 | 8-K | d201569d8k.htm |
| 2025-12-03 | 8-K | alny-20251202.htm |
| 2025-10-30 | 10-Q | alny-20250930.htm |